Cholesterol Education Program: Hearing Before the Subcommittee on Health and the Environment of the Committee on Energy and Commerce, House of Representatives, One Hundred First Congress, First Session, December 7, 1989U.S. Government Printing Office, 1990 - 149 pages Abstract: The hearing reported in this document considered the debate over the role government should play in cholesteral education. The value of the National Heart, Lung, and Blood Institute's massive National Cholesteral Education Program in questioned and the placement of such a high priority on cholesteral education while other national health problems exist is challenged. Two witnesses testify that the hazards of cholesteral have been greatly exaggerated. Methods of cholesteral screening (public screenings vs. private visits to doctors) and their relative merits are discusses. Other witnesses assert that the dangers of cholesteral are not overstated and that the government's role in publicizing cholesteral related information will help to lower suffering and death from chronic heart disease. |
Other editions - View all
Common terms and phrases
American Heart Association atherosclerosis benefits blood cholesterol levels Blood Institute cardiovascular disease Chairman Cholesterol Education Program cholesterol lowering cholesterol measurements cholesterol reduction cholestyramine clinical trials CONGRESS THE LIBRARY coronary events coronary heart disease cost death dietary cholesterol drug therapy effects elderly epidemiologic studies evidence follow-up Framingham Heart Study Framingham Study Garber Testimony gemfibrozil Gotto heart attacks heart disease risk high blood cholesterol high cholesterol levels Ischemic Heart Disease KUSSEROW laboratory LENFANT LIBRARY OF CONGRES LIBRARY OF CONGRESS Lipid Lipid Research Clinics lipoprotein lower cholesterol mg/dl middle-aged million MOORE Multiple Risk Factor myocardial infarction National Cholesterol Education National Heart NCEP guidelines NHLBI Oslo Study patients percent physicians placebo placebo group population Primary Prevention Trial PUBLIC CHOLESTEROL SCREENING public health public screening question rates recommended regression risk of heart saturated fat saturated fatty acids smoking STARE Testimony on Cholesterol total cholesterol WAXMAN WYDEN
Popular passages
Page 50 - Institute shall collect, identify, analyze, and disseminate on a timely basis, through publications and other appropriate means, to patients, families of patients, physicians and other health professionals, and the general public, information on research, prevention, diagnosis, and treatment of heart, blood vessel, lung, and blood diseases, the maintenance of health to reduce the incidence of such diseases, and on the use of blood and blood products and the management of blood resources.
Page 108 - Keys A, Anderson JT, Grande F. Serum cholesterol response to changes in the diet.
Page 107 - Hegsted DM. McGandy RB. Myers ML. Stare FJ. Quantitative effects of dietary fat on serum cholesterol in man.
Page 26 - INSPECTOR GENERAL DEPARTMENT OF HEALTH AND HUMAN SERVICES GOOD MORNING, MR. CHAIRMAN AND MEMBERS OF THE SUBCOMMITTEE, I AM RICHARD P.
Page 139 - Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in coronary drug project patients: longterm benefit with niacin.
Page 111 - Frick MH, Elo O, Haapa K, et al: Helsinki Heart Study: primaryprevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.
Page 141 - Harris T, Cook EF, Kannel WB, Goldman L. Proportional hazards analysis of risk factors for coronary heart disease in individuals aged 65 or older. The Framingham Heart Study.
Page 50 - Provides leadership for a national program in diseases of the heart, blood vessels, blood, lungs, and in the use of blood and the management of blood resources.
Page 139 - The Prevalence of High Blood Cholesterol Levels Among Adults in the United States.
Page 103 - A study of atherosclerosis regression in Macaca mulatta, IV: changes in coronary arteries from animals with atherosclerosis induced for 19 months and then regressed for 24 or 48 months at plasma cholesterol concentrations of 300 or 200 mg/dL. Exp Mol Pathol.